Published in Medical Letter on the CDC and FDA, April 22nd, 1996
The product is scheduled to be available in May 1996. Vaqta is indicated for active immunization against disease caused by hepatitis A virus (HAV) in persons two years of age and older. Hepatitis A is a highly contagious virus that attacks the liver.
Approximately 27,000 cases of the disease were reported to the U.S. Centers for Disease Control and Prevention (CDC) in 1994. However, the CDC estimates there are approximately 143,000...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.